PPARγ activation attenuates glucose intolerance induced by mTOR inhibition with rapamycin in rats

American Journal of Physiology - Endocrinology and Metabolism

Volumn 306, Issue 9, 2014, Pages

  Festuccia, William T ^a   Blanchard, Pierre Gilles ^b   Belchior, Thiago ^a   Chimin, Patricia ^a   Paschoal, Vivian A ^a   Magdalon, Juliana ^a   Hirabara, Sandro M ^a,c   Simões, Daniel ^a   St Pierre, Philippe ^b   Carpinelli, Angelo ^a   Marette, André ^b   Deshaies, Yves ^b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b LAVAL UNIVERSITY   (Canada)

^c UNIVERSIDADE CRUZEIRO DO SUL   (Brazil)

Author keywords

Gluconeogenesis; Glucose uptak; Insulin secretion; Mechanistic target of rapamycin; Peroxisome proliferatoractivated receptor ; Rapamycin; Rosiglitazone

Indexed keywords

C PEPTIDE; GLUCOSE; GLUCOSE 6 PHOSPHATASE; INSULIN; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); PROTEIN KINASE B; PYRUVIC ACID; RAPAMYCIN; ROSIGLITAZONE; TRIACYLGLYCEROL;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; ENZYME PHOSPHORYLATION; GLUCONEOGENESIS; GLUCOSE HOMEOSTASIS; GLUCOSE INTOLERANCE; GLUCOSE TRANSPORT; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN RELEASE; NONHUMAN; PRIORITY JOURNAL; RAT; SKELETAL MUSCLE;

GLUCONEOGENESIS; GLUCOSE UPTAKE; INSULIN SECRETION; MECHANISTIC TARGET OF RAPAMYCIN; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-Γ; RAPAMYCIN; ROSIGLITAZONE;

ANIMALS; CELLS, CULTURED; DRUG ANTAGONISM; GLUCOSE INTOLERANCE; INSULIN; INSULIN-SECRETING CELLS; MALE; MUSCLE, SKELETAL; PPAR GAMMA; RATS; RATS, SPRAGUE-DAWLEY; SIROLIMUS; THIAZOLIDINEDIONES; TOR SERINE-THREONINE KINASES;

EID: 84900539718     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00683.2013     Document Type: Article

References (45)

1. Aggarwal D, Fernandez ML, Soliman GA. Rapamycin, an mTOR inhibitor, disrupts triglyceride metabolism in guinea pigs. Metabolism 55: 794-802, 2006.
2. Anghel SI, Bedu E, Vivier CD, Descombes P, Desvergne B, Wahli W. Adipose tissue integrity as a prerequisite for systemic energy balance: a critical role for peroxisome proliferator-activated receptor gamma. J Biol Chem 282: 29946-29957, 2007.
3. Barlow AD, Nicholson ML, Herbert TP. Evidence for rapamycin toxicity in pancreatic beta-cells and a review of the underlying molecular mechanisms. Diabetes 62: 2674-2682, 2013.
4. Bell E, Cao X, Moibi JA, Greene SR, Young R, Trucco M, Gao Z, Matschinsky FM, Deng S, Markman JF, Naji A, Wolf BA. Rapamycin has a deleterious effect on MIN-6 cells and rat and human islets. Diabetes 52: 2731-2739, 2003.
5. Ben-Sahra I, Howell JJ, Asara JM, Manning BD. Stimulation of de novo pyrimidine synthesis by growth signaling through mTOR and S6K1. Science 339: 1323-1328, 2013.
6. Blanchard PG, Festuccia WT, Houde VP, St-Pierre P, Brule S, Turcotte V, Cote M, Bellmann K, Marette A, Deshaies Y. Major involvement of mTOR in the PPARgamma-induced stimulation of adipose tissue lipid uptake and fat accretion. J Lipid Res 53: 1117-1125, 2012.
7. Brattstrom C, Wilczek HE, Tyden G, Bottiger Y, Sawe J, Groth CG. Hypertriglyceridemia in renal transplant recipients treated with sirolimus. Transplant Proc 30: 3950-3951, 1998.
8. Crettaz M, Prentki M, Zaninetti D, Jeanrenaud B. Insulin resistance in soleus muscle from obese Zucker rats. Involvement of several defective sites. Biochem J 186: 525-534, 1980.
9. Deblon N, Bourgoin L, Veyrat-Durebex C, Peyrou M, Vinciguerra M, Caillon A, Maeder C, Fournier M, Montet X, Rohner-Jeanrenaud F, Foti M. Chronic mTOR inhibition by rapamycin induces muscle insulin resistance despite weight loss in rats. Br J Pharmacol 165: 2325-2340, 2012.
10. Fabian MC, Lakey JR, Rajotte RV, Kneteman NM. The efficacy and toxicity of rapamycin in murine islet transplantation. In vitro and in vivo studies. Transplantation 56: 1137-1142, 1993.
11. Fernandez-Bussy S, Akindipe O, Baz M, Gosain P, Rosenberg A, Zumberg M. Sirolimus-induced severe hypertriglyceridemia in a lung transplant recipient. Transplantation 89: 481-482, 2010.
12. Ferre P, Leturque A, Burnol AF, Penicaud L, Girard J. A method to quantify glucose utilization in vivo in skeletal muscle and white adipose tissue of the anaesthetized rat. Biochem J 228: 103-110, 1985.
13. Festuccia WT, Blanchard PG, Turcotte V, Laplante M, Sariahmetoglu M, Brindley DN, Deshaies Y. Depot-specific effects of the PPARgamma agonist rosiglitazone on adipose tissue glucose uptake and metabolism. J Lipid Res 50: 1185-1194, 2009.
14. Festuccia WT, Deshaies Y. Depot specificities of PPAR gamma ligand actions on lipid and glucose metabolism and their implication in PPAR gamma-mediated body fat redistribution. Clin Lipid 4: 633-642, 2009.
15. Fraenkel M, Ketzinel-Gilad M, Ariav Y, Pappo O, Karaca M, Castel J, Berthault MF, Magnan C, Cerasi E, Kaiser N, Leibowitz G. mTOR inhibition by rapamycin prevents beta-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes. Diabetes 57: 945-957, 2008.
16. Houde VP, Brule S, Festuccia WT, Blanchard PG, Bellmann K, Deshaies Y, Marette A. Chronic rapamycin treatment causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and impairing lipid deposition in adipose tissue. Diabetes 59: 1338-1348, 2010.
17. Huang J, Manning BD. The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. Biochem J 412: 179-190, 2008.
18. Khamzina L, Veilleux A, Bergeron S, Marette A. Increased activation of the mammalian target of rapamycin pathway in liver and skeletal muscle of obese rats: possible involvement in obesity-linked insulin resistance. Endocrinology 146: 1473-1481, 2005.
19. Kim JE, Chen J. regulation of peroxisome proliferator-activated receptorgamma activity by mammalian target of rapamycin and amino acids in adipogenesis. Diabetes 53: 2748-2756, 2004.
20. Lacy PE, Kostianovsky M. Method for the isolation of intact islets of Langerhans from the rat pancreas. Diabetes 16: 35-39, 1967.
21. Lamming DW, Ye L, Katajisto P, Goncalves MD, Saitoh M, Stevens DM, Davis JG, Salmon AB, Richardson A, Ahima RS, Guertin DA, Sabatini DM, Baur JA. Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science 335: 1638-1643, 2012.
22. Laplante M, Sabatini DM. mTOR signaling at a glance. J Cell Sci 122: 3589-3594, 2009.
23. Laplante M, Sell H, MacNaul KL, Richard D, Berger JP, Deshaies Y. PPAR-gamma activation mediates adipose depot-specific effects on gene expression and lipoprotein lipase activity: mechanisms for modulation of postprandial lipemia and differential adipose accretion. Diabetes 52: 291-299, 2003.
24. Le Bacquer O, Queniat G, Gmyr V, Kerr-Conte J, Lefebvre B, Pattou F. mTORC1 and mTORC2 regulate insulin secretion through Akt in INS-1 cells. J Endocrinol 216: 21-29, 2013.
25. Lustig Y, Ruas JL, Estall JL, Lo JC, Devarakonda S, Laznik D, Choi JH, Ono H, Olsen JV, Spiegelman BM. Separation of the gluconeogenic and mitochondrial functions of PGC-1{alpha} through S6 kinase. Genes Dev 25: 1232-1244, 2011.
26. Maeda K, Shioi T, Kosugi R, Yoshida Y, Takahashi K, Machida Y, Izumi T. Rapamycin ameliorates experimental autoimmune myocarditis. Int Heart J 46: 513-530, 2005.
27. Malizzia LJ, Hsu A. Temsirolimus, an mTOR inhibitor for treatment of patients with advanced renal cell carcinoma. Clin J Oncol Nurs 12: 639-646, 2008.
28. Marcelli-Tourvieille S, Hubert T, Moerman E, Gmyr V, Kerr-Conte J, Nunes B, Dherbomez M, Vandewalle B, Pattou F, Vantyghem MC. In vivo and in vitro effect of sirolimus on insulin secretion. Transplantation 83: 532-538, 2007.
29. Menon S, Manning BD. Common corruption of the mTOR signaling network in human tumors. Oncogene 27, Suppl 2: S43-S51, 2008.
30. Morrisett JD, Abdel-Fattah G, Hoogeveen R, Mitchell E, Ballantyne CM, Pownall HJ, Opekun AR, Jaffe JS, Oppermann S, Kahan BD. Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients. J Lipid Res 43: 1170-1180, 2002.
31. Nawrocki AR, Rajala MW, Tomas E, Pajvani UB, Saha AK, Trumbauer ME, Pang Z, Chen AS, Ruderman NB, Chen H, Rossetti L, Scherer PE. Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor gamma agonists. J Biol Chem 281: 2654-2660, 2006.
32. Puigserver P, Rhee J, Donovan J, Walkey CJ, Yoon JC, Oriente F, Kitamura Y, Altomonte J, Dong H, Accili D, Spiegelman BM. Insulinregulated hepatic gluconeogenesis through FOXO1-PGC-1alpha interaction. Nature 423: 550-555, 2003.
33. Ricoult SJ, Manning BD. The multifaceted role of mTORC1 in the control of lipid metabolism. EMBO Rep 14: 242-251, 2013.
34. Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, Markhard AL, Sabatini DM. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 22: 159-168, 2006.
35. Shioi T, McMullen JR, Tarnavski O, Converso K, Sherwood MC, Manning WJ, Izumo S. Rapamycin attenuates load-induced cardiac hypertrophy in mice. Circulation 107: 1664-1670, 2003.
36. Thoreen CC, Sabatini DM. Rapamycin inhibits mTORC1, but not completely. Autophagy 5: 725-726, 2009.
37. Tremblay F, Brûlé S, Hee Um S, Li Y, Masuda K, Roden M, Sun XJ, Krebs M, Polakiewicz RD, Thomas G, Marette A. Identification of IRS-1 Ser-1101 as a target of S6K1 in nutrient-and obesity-induced insulin resistance. Proc Natl Acad Sci USA 104: 14056-14061, 2007.
38. Tremblay F, Gagnon A, Veilleux A, Sorisky A, Marette A. Activation of the mammalian target of rapamycin pathway acutely inhibits insulin signaling to Akt and glucose transport in 3T3-L1 and human adipocytes. Endocrinology 146: 1328-1337, 2005.
39. Tremblay F, Marette A. Amino acid and insulin signaling via the mTOR/p70 S6 kinase pathway. A negative feedback mechanism leading to insulin resistance in skeletal muscle cells. J Biol Chem 276: 38052-38060, 2001.
40. Um SH, D'Alessio D, Thomas G. Nutrient overload, insulin resistance, and ribosomal protein S6 kinase 1, S6K1. Cell Metab 3: 393-402, 2006.
41. Um SH, Frigerio F, Watanabe M, Picard F, Joaquin M, Sticker M, Fumagalli S, Allegrini PR, Kozma SC, Auwerx J, Thomas G. Absence of S6K1 protects against age-and diet-induced obesity while enhancing insulin sensitivity. Nature 431: 200-205, 2004.
42. Veilleux A, Houde VP, Bellmann K, Marette A. Chronic inhibition of the mTORC1/S6K1 pathway increases insulin-induced PI3K activity but inhibits Akt2 and glucose transport stimulation in 3T3-L1 adipocytes. Mol Endocrinol 24: 766-778, 2010.
43. Ye L, Varamini B, Lamming DW, Sabatini DM, Baur JA. Rapamycin has a biphasic effect on insulin sensitivity in C2C12 myotubes due to sequential disruption of mTORC1 and mTORC2. Front Genet 3: 177, 2012.
44. Zhang N, Su D, Qu S, Tse T, Bottino R, Balamurugan AN, Xu J, Bromberg JS, Dong HH. Sirolimus is associated with reduced islet engraftment and impaired beta-cell function. Diabetes 55: 2429-2436, 2006.
45. Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 12: 21-35, 2012.